Intermune's 'minor improvement' gets $25k-a-year price in France
This article was originally published in Scrip
Intermune is "very, very pleased" with its French price for its orphan drug Esbriet (pirfenidone) for mild to moderate idiopathic pulmonary fibrosis. CEPS, France's pricing committee has approved an ex-factory price of €25,000 per patient per year, which is on a par with the price of Actelion's Tracleer (bosentan). It is also higher than prices approved for Novartis' Gilenya and Elan/Biogen's Tysabri (natalizumab), both for MS, €22,700 and €23,500 respectively.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.